WAVE LIFE SCIENCES LTD. Variable Lease, Cost
WAVE LIFE SCIENCES LTD. (WVE) reported Variable Lease, Cost of $3.08 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. variable lease, cost for fiscal 2025 was $3.08M, a 2.84% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. variable lease, cost for fiscal 2024 was $3.00M, a 7.15% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. variable lease, cost for fiscal 2023 was $2.80M, a 11.56% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. variable lease, cost for fiscal 2022 was $2.51M, a 16.65% increase from fiscal 2021.
| Period end | Variable Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $3.08M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $2.80M 10-K · filed 2026-02-26 |
| 2022-12-31 | $2.51M 10-K · filed 2025-03-04 |
| 2021-12-31 | $2.15M 10-K · filed 2023-03-23 |
| 2020-12-31 | $1.98M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |